Covid-19 and diabetes: a complex bidirectional relationship
File(s)fendo-11-582936.pdf (1.48 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Covid-19 is a recently-emerged infectious disease caused by the novel severe acute respiratory syndrome coronavirus SARS-CoV2. SARS-CoV2 differs from previous coronavirus infections (SARS and MERS) due to its high infectivity (reproduction value, R0, typically 2-4) and pre- or asymptomatic transmission, properties that have contributed to the current global Covid-19 pandemic. Identified risk factors for disease severity and death from SARS-Cov2 infection include older age, male sex, diabetes, obesity and hypertension. The reasons for these associations are still largely obscure. Evidence is also emerging that SARS-CoV2 infection exacerbates the underlying pathophysiology of hyperglycemia in people with diabetes. Here, we discuss potential mechanisms through which diabetes may affect the risk of more severe outcomes in Covid-19 and, additionally, how diabetic emergencies and longer term pathology may be aggravated by infection with the virus. We consider roles for the immune system, the observed phenomenon of microangiopathy in severe Covid-19 infection and the potential for direct viral toxicity on metabolically-relevant tissues including pancreatic beta cells and targets of insulin action.
Date Issued
2020-10-08
Date Acceptance
2020-09-08
Citation
Frontiers in Endocrinology, 2020, 11
ISSN
1664-2392
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Endocrinology
Volume
11
Copyright Statement
© 2020 Muniangi-Muhitu, Akalestou, Salem, Misra, Oliver and Rutter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
License URL
Sponsor
INNOVATIVE MEDICINES INITIATIVE
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33133024
Grant Number
115881
Subjects
Covid-19
diabetes
ketoacidosis
management
microangiopathy
Publication Status
Published
Coverage Spatial
Switzerland
Article Number
ARTN 582936